SMS Pharma revenue down 9%
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company sees the business reaching $100mn
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Subscribe To Our Newsletter & Stay Updated